Brief: Talaris Therapeutics Announces Plans To Explore Strategic Alternatives And Implements Restructuring Plan
Brief: Talaris Therapeutics Announces Q3 Financial Results
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific
U.S. STOCKS ON THE MOVE-Vertiv, U.S. energy, Gold miners
U.S. STOCKS ON THE MOVE-AT&T, Blackstone, HOOKIPA Pharma
Talaris Therapeutics falls after patient dies in late-stage trial
Brief: Talaris Therapeutics Provides Update On Freedom-1 Phase 3 Clinical Trial
Brief: Talaris Therapeutics Files For Mixed Shelf Of Up To $250 Million
Brief: Talaris Therapeutics Reports Q2 Loss Per Share Of $0.44
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
U.S. RESEARCH ROUNDUP-Chevron, Occidental Petroleum, Talaris Therapeutics
Brief: Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update
Brief: Talaris Therapeutics Presents Additional Phase 2 Data And Analyses At American Transplant Congress 2022
Brief: Talaris Therapeutics Announces Changes To Board Of Directors
Brief: Talaris Therapeutics Announces First Quarter Results
Brief: Talaris Therapeutics Presents Data On COVID-19 Outcomes Among Kidney Transplant Patients Treated With FCR001
Brief: Talaris Therapeutics Reports Q4 Loss Per Share Of $0.35
Brief: Talaris Therapeutics Added To Nasdaq Biotechnology Index